Ohtori R, Sato H, Fukuda S, Ueda T, Koide R, Kanda Y, Kiuchi Y, Oguchi K
Department of Ophthalmology, Showa University School of Medicine, 1-5-8 Hatanodai, Tokyo, Shinagawa-ku, 142-0064, Japan.
Exp Eye Res. 1998 Apr;66(4):487-94. doi: 10.1006/exer.1997.0448.
The microdialysis method was used to evaluate the pharmacokinetics of the beta-adrenergic antagonists carteolol and timolol and the new ophthalmic solution WP-934 in rabbit aqueous humor, following instillation. A probe with a microdialysis membrane (length, 5 mm; diameter, 0.2 mm) was implanted in the anterior chamber of the pigmented rabbit and perfused with Ringer's solution. Twenty microliters of 0.5% timolol maleate (0.5% Timoptol(R)), 2% carteolol hydrochloride (2% Mikelan(R)), or a novel preparation of 0.5% timolol maleate (WP-934) that gels after instillation were then instilled. The concentrations of these drugs in dialysates were measured using high-performance liquid chromatography and an electrochemical detection system. In vitro relative recovery of the membrane with timolol and carteolol was approximately 17.5% and 21. 6%, respectively. Timolol and carteolol levels in aqueous humor increased rapidly after instillation of Timoptol and Mikelan and reached maximal levels (Cmax) within 60 minutes. The Cmax of carteolol (4.25 microg ml-1) was lower than that of timolol (5.52 microg ml-1), suggesting that the corneal permeability of timolol is higher than that of carteolol. After instillation of WP-934, the Cmax of timolol (12.32 microg ml-1) was 2.2-fold higher than that after instillation of Timoptol. However, t1/2 values of beta-adrenergic antagonists after instillation of the three preparations were not significantly different. These data suggest that the microdialysis technique is useful for continuous monitoring of aqueous levels of beta-blockers and for analysis of their pharmacokinetic parameters while requiring much fewer animals than conventional sampling with paracentesis.
采用微透析法评估β-肾上腺素能拮抗剂卡替洛尔、噻吗洛尔以及新型眼用溶液WP-934滴入兔眼房水后的药代动力学。将带有微透析膜(长度5 mm;直径0.2 mm)的探针植入有色兔的前房,并用林格氏液灌注。然后分别滴入20微升0.5%马来酸噻吗洛尔(0.5%噻吗洛尔滴眼液)、2%盐酸卡替洛尔(2%米卡朗)或滴入后会形成凝胶的新型0.5%马来酸噻吗洛尔制剂(WP-934)。使用高效液相色谱和电化学检测系统测量透析液中这些药物的浓度。膜对噻吗洛尔和卡替洛尔的体外相对回收率分别约为17.5%和21.6%。滴入噻吗洛尔滴眼液和米卡朗后,房水中噻吗洛尔和卡替洛尔的水平迅速升高,并在60分钟内达到最高水平(Cmax)。卡替洛尔的Cmax(4.25微克/毫升)低于噻吗洛尔的Cmax(5.52微克/毫升),表明噻吗洛尔的角膜通透性高于卡替洛尔。滴入WP-934后,噻吗洛尔的Cmax(12.32微克/毫升)比滴入噻吗洛尔滴眼液后高2.2倍。然而,滴入这三种制剂后β-肾上腺素能拮抗剂的t1/2值无显著差异。这些数据表明,微透析技术可用于连续监测β受体阻滞剂的房水水平及其药代动力学参数分析,同时所需动物数量比传统穿刺采样少得多。